Special Issue

Neurodegenerative Diseases: Recent Advances and Future Perspectives, 2nd Edition

Message from the Guest Editors

This Special Issue is the second volume of "Neurodegenerative Diseases: Recent Advances and Future Perspectives". Neurodegenerative disorders impact a significant portion of the global population, and their prevalence is increasing in tandem with rising life expectancies. Conditions such as Alzheimer's disease (AD). Parkinson's disease (PD). Huntington's disease. amyotrophic lateral sclerosis (ALS), frontotemporal dementia, ataxias, and glaucoma are characterized by progressive neuronal deterioration and the disruption of neural connectivity, leading to impairment in mobility. coordination, strength, sensation, cognition, and vision. This Special Issue, under the direction of Dr. López-Cuenca and Dr. De Hoz, will highlight recent advances in the fields of basic, translational, and clinical research in neurodegenerative diseases. It aims at expanding knowledge on the pathophysiological mechanisms and therapeutic pathways for these disabling diseases.

Guest Editors

Dr. Inés López-Cuenca

- 1. Ramon Castroviejo Institute of Ophthalmologic Research, Complutense University of Madrid, 28040 Madrid, Spain
- 2. Health Research Institute of the Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain

Dr. Rosa De Hoz

- 1. Ramon Castroviejo Institute of Ophthalmologic Research, Complutense University of Madrid, 28040 Madrid, Spain
- Health Research Institute of the Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain
- 3. Department of Immunology, Ophthalmology and ENT, Faculty of Optics and Optometry, Complutense University of Madrid, 28037 Madrid, Spain

Deadline for manuscript submissions

closed (25 June 2025)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/203933

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).